کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2796125 1568795 2016 9 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Aspirin for primary prevention of cardiovascular disease in patients with diabetes: A meta-analysis
ترجمه فارسی عنوان
آسپرین برای پیشگیری اولیه از بیماری قلبی عروقی در بیماران مبتلا به دیابت: یک متاآنالیز
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی علوم غدد
چکیده انگلیسی


• CVD is the leading cause of morbidity and mortality for patients with diabetes.
• The benefit of aspirin used for CVD primary prevention is controversial.
• Meta-analyses report aspirin does not prevent CVD endpoints nor increase bleeding.
• Several atherosclerotic endpoints were not included in previous meta-analyses.
• This meta-analysis found no difference of atherosclerotic events with aspirin vs. placebo.

AimsAspirin use for primary prevention of cardiovascular disease (CVD) is controversial, especially in patients with diabetes. The objective of this meta-analysis was to evaluate aspirin’s safety and efficacy for primary prevention of CVD [fatal or nonfatal myocardial infarction (MI), fatal or nonfatal stroke, angina, transient ischemic attack (TIA), peripheral artery disease (PAD) and revascularization] in patients with diabetes.MethodsA literature search was conducted using the terms cardiovascular disease, aspirin, diabetes mellitus to identify trials of patients with diabetes who received aspirin for primary prevention of CVD. Study sample size, and ischemic and bleeding events were extracted and analyzed using RevMan 5.2.7.ResultsIn total, 6 studies (n = 10,117) met criteria. Aspirin doses ranged from 100 mg every other day to 650 mg daily. Follow-up ranged from 3.6 to 10.1 years. In patients with diabetes, there was no difference between aspirin and placebo with respect to the risk of all cause mortality (OR 0.93, 95% CI 0.81–1.06), or individual atherosclerotic events compared to placebo. There were no differences in bleeding (OR 2.53, 95% CI 0.77–8.34), GI bleeding (OR 2.14, 95% CI 0.63–7.33) or hemorrhagic stroke rates (OR 0.90, 0.34–2.33) between groups.ConclusionsIt remains unclear whether aspirin may reduce the occurrence of a first atherosclerotic event or mortality in patients with diabetes. More research on this use of aspirin in patients with diabetes is required to supplement currently available research.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Diabetes Research and Clinical Practice - Volume 120, October 2016, Pages 31–39
نویسندگان
, , , ,